BRAIN and NERVE－神経研究の進歩73巻5号

2021年05月発行

増大特集 中枢神経の自己免疫性・炎症性疾患ハンドブック

第2章　疾患各論

新しい自己抗体関連脳炎・脳症—抗mGluR1抗体陽性脳炎，抗IgLON5抗体関連疾患，自己免疫性GFAPアストロサイトパチー

著者： 吉倉延亮¹ 木村暁夫¹ 下畑享良¹

所属機関： ¹岐阜大学大学院医学系研究科脳神経内科学分野

ページ範囲：P.631 - P.639

文献概要

自己抗体関連脳炎・脳症では，多彩な神経症候が出現する。抗mGluR1抗体陽性脳炎は，主に小脳性運動失調症を呈し，異常行動や不随意運動症を伴う場合がある。抗IgLON5抗体関連疾患は，特徴的な睡眠障害を呈するが，神経変性疾患との鑑別を要する場合がある。自己免疫性GFAPアストロサイトパチーは，原因不明の髄膜脳脊髄炎に認められる。これらは治療可能な疾患であることから，早期の適切な診断が不可欠である。

参考文献

1）Pin JP, Duvoisin R: The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34: 1-26, 1995

2）Sillevis Smitt PA, Kinoshita A, De Leeuw B, Moll W, Coesmans M, et al: Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342: 21-27, 2000

3）Coesmans M, Sillevis Smitt PA, Linden DJ, Shigemoto R, Hirano T, et al: Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 53: 325-336, 2003

4）Spatola M, Pedrol MP, Maudes E, Simabukuro M, Muñiz-Castrillo S, et al: Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology 95: e3012-e3025, 2020［doi: 10.1212/WNL.0000000000010854］

5）Yoshikura N, Kimura A, Fukata M, Fukata Y, Yokoi N, et al: Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies. J Neuroimmunol 319: 63-67, 2018

6）Bien CG, Braig S, Bien C: Antibodies against metabotropic glutamate receptor type 1 in a toddler with acute cerebellitis. J Neuroimmunol 348: 577366, 2020［doi: 10.1016/j.jneuroim.2020.577366］

7）Lopez-Chiriboga AS, Komorowski L, Kümpfel T, Probst C, Hinson SR, et al: Metabotropic glutamate receptor type 1 autoimmunity: clinical features and treatment outcomes. Neurology 86: 1009-1013, 2016

8）Yoshida K, Kuwabara S, Nakamura K, Abe R, Matsushima A, et al: Idiopathic cerebellar ataxia (IDCA): diagnostic criteria and clinical analyses of 63 Japanese patients. J Neurol Sci 384: 30-35, 2018

9）Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, et al: A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13: 575-586, 2014

10）Sabater L, Planagumà J, Dalmau J, Graus F: Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation 13: 226, 2016［doi: 10.1186/s12974-016-0689-1］

11）Landa J, Gaig C, Plaguma J, Saiz A, Antonell A, et al: Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration. Ann Neurol 88: 1023-1027, 2020

12）Gaig C, Compta Y: Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. Curr Opin Neurol 32: 493-499, 2019

13）Erro ME, Sabater L, Martínez L, Herrera M, Ostolaza A, et al: Anti-IGLON5 disease: a new case without neuropathologic evidence of brainstem tauopathy. Neurol Neuroimmunol Neuroinflamm 7: e651, 2019［doi: 10.1212/NXI.0000000000000651］

14）Fuseya K, Kimura A, Yoshikura N, Yamada M, Hayashi Y, et al: Corticobasal syndrome in a patient with anti-IgLON5 antibodies. Mov Disord Clin Pract 7: 557-559, 2020

15）Gaig C, Graus F, Compta Y, Högl B, Bataller L, et al: Clinical manifestations of the anti-IgLON5 disease. Neurology 88: 1736-1743, 2017

16）Chen H, Wu J, Irani SR: Distinctive magnetic resonance imaging findings in iglon5 antibody disease. JAMA Neurol 77: 125-126, 2020

17）Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, et al: Criteria for the diagnosis of corticobasal degeneration. Neurology 80: 496-503, 2013

18）Muñoz-Lopetegi A, Graus F, Dalmau J, Santamaria J: Sleep disorders in autoimmune encephalitis. Lancet Neurol 19: 1010-1022, 2020

19）Cabezudo-García P, Mena-Vázquez N, Torrús GE, Serrano-Castro P: Response to immunotherapy in anti-IgLON5 disease: a systematic review. Acta Neurol Scand 141: 263-270, 2020

20）Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK: IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 4: e385, 2017［doi: 10.1212/NXI.0000000000000385］

21）Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, et al: Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 73: 1297-1307, 2016

22）Long Y, Liang J, Xu H, Huang Q, Yang J, et al: Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective study. Eur J Neurol 25: 477-483, 2018

23）Iorio R, Damato V, Evoli A, Gessi M, Gaudino S, et al: Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry 89: 138-146, 2018

24）Kimura A, Takekoshi A, Yoshikura N, Hayashi Y, Shimohata T: Clinical characteristics of autoimmune GFAP astrocytopathy. J Neuroimmunol 332: 91-98, 2019

25）Dubey D, Hinson SR, Jolliffe EA, Zekeridou A, Flanagan EP, et al: Autoimmune GFAP astrocytopathy: prospective evaluation of 90 patients in 1 year. J Neuroimmunol 321: 157-163, 2018

26）Kunchok A, Zekeridou A, McKeon A: Autoimmune glial fibrillary acidic protein astrocytopathy. Curr Opin Neurol 32: 452-458, 2019

27）Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, et al: Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 81: 298-309, 2017

28）Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, et al: Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. J Neurol Neurosurg Psychiatry 90: 488-490, 2019

29）Kudo T, Kimura A, Higashida K, Yamada M, Hayashi Y, et al: Autoimmune glial fibrillary acidic protein astrocytopathy presenting with slowly progressive myelitis and longitudinally extensive spinal cord lesions. Intern Med 59: 2777-2781, 2020

30）Yang X, Liang J, Huang Q, Xu H, Gao C, et al: Treatment of autoimmune glial fibrillary acidic protein astrocytopathy: follow-up in 7 cases. Neuroimmunomodulation 24: 113-119, 2017